Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau-targeted vaccine study in early Alzheimer's disease
NL-OMON55583Phase 2Active, not recruiting
- Sponsor
- AC Immune SA
- Start
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ACI-35.030 or placebo, JACI-35.054 or placebo and Sequential ACI-35.030 and JACI-35.054 (3 arms). Primary endpoints: Safety and tolerability and Immunogenicity: anti-pTau IgG in serum. Started Sep 2019; status: active, not recruiting.
02
Drugs
ACI-35.030JACI-35.054
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON55583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55583.